The global breast cancer diagnostics market size is expected to reach around US$ 7.1 billion by 2030 from US$ 3.75 billion in 2021 and is expected to grow at an impressive double-digit rate of 7.3% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global breast cancer diagnostics market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
The growth of the breast cancer diagnostics market can be attributed to expanding government initiatives to improve cancer diagnosis and screening rates, as well as rising cancer prevalence.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1524
Why should you invest in this report?
If you are aiming to enter the global breast cancer diagnostics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for breast cancer diagnostics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global breast cancer diagnostics market include:
- Genomic Health
- NanoString Technologies Inc.
- Paragon Biosciences LLC
- Devicor Medical Products Inc.
- AstraZeneca
- Quest Diagnostics Incorporated
- Koninklijke Philips N.V.
- Siemens AG
- Biocept Inc.
- Epigenomics Inc.
Market Segmentation:
By Type
- Imaging
- Biopsy
- Genomic Tests
- Blood Tests
- Others
By Product
- Platform-based Products
- Instrument-based Products
By Application
- Screening
- Diagnostic and Predictive
- Prognostic
- Others
By End Use
- Hospitals & Clinics
- Diagnostic Centers & Medical Laboratories
- Others
Regional Analysis:
The geographical analysis of the global breast cancer diagnostics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global breast cancer diagnostics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global breast cancer diagnostics market in 2030?
- What is the expected CAGR for the breast cancer diagnostics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global breast cancer diagnostics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Breast Cancer Diagnostics Market
5.1. COVID-19 Landscape: Breast Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Breast Cancer Diagnostics Market, By Product
8.1. Breast Cancer Diagnostics Market, by Product Type, 2021-2030
8.1.1. Platform-based Products
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Instrument-based Products
8.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Breast Cancer Diagnostics Market, By Type
9.1. Breast Cancer Diagnostics Market, by Type, 2021-2030
9.1.1. Imaging
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Biopsy
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Genomic Tests
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Blood Tests
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Breast Cancer Diagnostics Market, By Application Type
10.1. Breast Cancer Diagnostics Market, by Application Type, 2021-2030
10.1.1. Screening
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Diagnostic and Predictive
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Prognostic
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Breast Cancer Diagnostics Market, By End Use Type
11.1. Breast Cancer Diagnostics Market, by End Use Type, 2021-2030
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast (2019-2030)
11.1.2. Diagnostic Centers & Medical Laboratories
11.1.2.1. Market Revenue and Forecast (2019-2030)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 12. Global Breast Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.2. Market Revenue and Forecast, by Type (2019-2030)
12.1.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.1.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.5.2. Market Revenue and Forecast, by Type (2019-2030)
12.1.5.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.1.5.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.6.2. Market Revenue and Forecast, by Type (2019-2030)
12.1.6.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.1.6.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.2. Market Revenue and Forecast, by Type (2019-2030)
12.2.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.2.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.5.2. Market Revenue and Forecast, by Type (2019-2030)
12.2.5.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.2.5.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.6.2. Market Revenue and Forecast, by Type (2019-2030)
12.2.6.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.2.6.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.7.2. Market Revenue and Forecast, by Type (2019-2030)
12.2.7.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.2.7.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.8.2. Market Revenue and Forecast, by Type (2019-2030)
12.2.8.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.2.8.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.2. Market Revenue and Forecast, by Type (2019-2030)
12.3.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.3.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.5.2. Market Revenue and Forecast, by Type (2019-2030)
12.3.5.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.3.5.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.6.2. Market Revenue and Forecast, by Type (2019-2030)
12.3.6.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.3.6.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.7.2. Market Revenue and Forecast, by Type (2019-2030)
12.3.7.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.3.7.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.8.2. Market Revenue and Forecast, by Type (2019-2030)
12.3.8.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.3.8.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.2. Market Revenue and Forecast, by Type (2019-2030)
12.4.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.4.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.5.2. Market Revenue and Forecast, by Type (2019-2030)
12.4.5.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.4.5.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.6.2. Market Revenue and Forecast, by Type (2019-2030)
12.4.6.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.4.6.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.7.2. Market Revenue and Forecast, by Type (2019-2030)
12.4.7.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.4.7.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.8.2. Market Revenue and Forecast, by Type (2019-2030)
12.4.8.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.4.8.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.2. Market Revenue and Forecast, by Type (2019-2030)
12.5.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.5.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.5.2. Market Revenue and Forecast, by Type (2019-2030)
12.5.5.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.5.5.4. Market Revenue and Forecast, by End Use Type (2019-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.6.2. Market Revenue and Forecast, by Type (2019-2030)
12.5.6.3. Market Revenue and Forecast, by Application Type (2019-2030)
12.5.6.4. Market Revenue and Forecast, by End Use Type (2019-2030)
Chapter 13. Company Profiles
13.1. Genomic Health
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. NanoString Technologies Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Paragon Biosciences LLC
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Devicor Medical Products Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Quest Diagnostics Incorporated
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Koninklijke Philips N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Siemens AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Biocept Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Epigenomics Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1524
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments